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Purpose: Locally advanced rectal cancer (LARC) is managed by chemoradiotherapy (CRT), followed by surgery. Herein 
we reported patients with metastases during or after CRT. 
Methods: Data of patients with LARC who received CRT from 2008 to 2017 were reviewed. Patients with metastases after 
CRT were included. Those with metastatic tumors at the initial diagnosis were excluded. 
Results: Fourteen patients (1.3%) of 1,092 who received CRT presented with metastases. Magnetic resonance circumfer-
ential resection margin (mrCRM) and mesorectal lymph nodes (LNs) were positive in 12 patients (85.7%). Meanwhile, 
magnetic resonance extramural vascular invasion (mrEMVI) was positive in 10 patients (71.4%). Magnetic resonance tu-
mor regression grade (mrTRG) 4 and mrTRG5 was detected in 5 and 1 patient respectively. Ten patients (71.4%) under-
went combined surgery and 3 (21.4%) received palliative chemotherapy. 
Conclusion: Patients with metastases after CRT showed a higher rate of positive mrCRM, mrEMVI, mesorectal LNs, and 
poor tumor response. Further studies with a large number of patients are necessary for better survival outcomes in LARC. 
Keywords: Locally advanced rectal cancer; Chemoradiation; Risk factors; Distant metastases
INTRODUCTION 
In the past, locally advanced rectal cancers (LARCs) were defined 
as stage T3 to T4 cancers or those with positive lymph nodes (LNs) 
according to the American Joint Committee on Cancer staging 
system [1]. Conversely, some authors consider only T4 as a LARC, 
regardless of whether it is associated with positive LNs [2]. Cur-
rently, the typical definition of LARCs is those which require mul-
tidisciplinary management and includes tumors extending beyond 
the total mesorectal excision (TME) planes that need pelvic exen-
teration, advanced T stage (≥ T3) tumors or positive mesorectal 
LNs with or without extramural venous invasion (EMVI) and pos-
itive circumferential resection margin (CRM) [3, 4].
According to the National Comprehensive Cancer Network guide-
lines, there are some treatment strategies for LARC. Moreover, to-
tal neoadjuvant therapy has been widely studied around the world. 
However, neoadjuvant long-course chemoradiotherapy (CRT) 
over 5 weeks, followed by TME after a gap period of 8 to 10 weeks, 
and then postoperative chemotherapy was traditionally used in 
Korea and Western countries [5]. Regarding neoadjuvant chemo-
therapy, a small dose of capecitabine is used as a radiosensitizer, 
which is a safe and tolerable drug that increases the rate of sphinc-
ter-saving surgery [5, 6]. After the completion of CRT, a waiting 
period is mandatory for tumor response and/or regression because 
the rectal cancer response to CRT is time-dependent. Meanwhile, 
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this gap period is used for the evaluation and restaging of the tu-
mor after treatment [7]. 
Multiple studies have demonstrated the benefits of CRT, includ-
ing downstaging and downsizing, which in turn enhance the pos-
sibility of sphincter preservation surgery [7-9]. Although preop-
erative CRT has markedly decreased local recurrence with a vari-
ety of tumor responses ranging from pathologically complete re-
sponse to no response or even progression during treatment, its 
role in the control of distant metastases is considered a matter of 
concern [9-11]. 
During the gap period before surgery, we sometimes encounter 
patients with metastases during or after completion of CRT for 
whom combined surgery or salvage chemotherapy is conducted 
but with poor outcomes. Therefore, we aimed to summarize the 




The retrospectively collected data of 1,092 patients with LARC 
who received preoperative CRT at Department of Surgery, Sever-
ance Hospital, Yonsei University College of Medicine (Seoul, Ko-
rea) from 2008 to 2017 were reviewed. We included patients who 
developed organ metastases during or after the completion of CRT. 
Those with metastatic tumors present at initial imaging were ex-
cluded. The clinical and radiological characteristics of the patients 
were reported. The study was approved by the Institutional Review 
Board of Severance Hospital (No. 4-2019-1347). We got the writ-
ten informed consent from the patients.
Preoperative assessment and neoadjuvant CRT
Patients were evaluated by clinical examination, abdominopelvic 
computed tomography (CT) scan, serum carcinoembryonic anti-
gen (CEA) level, chest CT, and pelvic magnetic resonance imag-
ing (MRI). All patients were diagnosed with LARC using MRI. 
The tumor pathology was determined to be adenocarcinoma by 
colonoscopic biopsy.
Patients received neoadjuvant CRT (50.4 Gy in 28 fractions) for 
5 to 6 weeks with capecitabine as a radiosensitizer. All patients were 
evaluated by abdominopelvic CT, chest CT, pelvic MRI, and CEA 
level after an 8- to 10-week gap to evaluate response.
Methods of intervention
Patients diagnosed with metastases in the waiting period after CRT 
were requested to wait till the multidisciplinary team meeting to 
receive a final decision regarding their treatment. Those who pre-
sented with LARC associated with resectable metastases to the 
liver and/or lung with or without peritoneal metastases and had 
no contraindications for surgery underwent combined resection 
either directly or after upfront chemotherapy (if R0 resection was 
possible). All decisions were made by a colorectal surgeon as well 
as a hepatobiliary and/or cardiothoracic surgeon. Contrarily, pa-
tients who developed disseminated metastases to multiple organs 
or bones or those with any contraindications for resection received 
a palliative regimen of chemotherapy either capecitabine, FOLFOX 
(folinic acid +5 fluorouracil +oxaliplatin) or FOLFIRI (folinic 
acid+5 fluorouracil+irinotecan) with or without target agents.
Definitions, follow-up, statistics 
In our study, metastasis is defined as the distant spread of the tu-
mor to other organs (liver, lung, peritoneum, and others) exclud-
ing regional LNs while the LARC is under treatment with or after 
completion of CRT. The mean time for the detection of metasta-
ses post-CRT is the time interval between the initiation of treat-
ment with CRT and the detection of metastases to other organs. 
Magnetic resonance CRM (mrCRM) is defined as the distance 
between the tumor tissue and the surrounding radial margin and 
is considered positive when it is ≤ 1 mm on MRI [12]. On the other 
hand, magnetic resonance tumor regression grade (mrTRG) is 
defined as the radiological imaging of the tumor response after 
CRT based on the presence of fibrosis or tumor signal intensity 
[13]. mrTRG1 means no evidence of tumor (complete response); 
mrTRG2, dense fibrosis without residual tumor (good response); 
mrTRG3, ≥ 50% fibrosis with the intermediate signal intensity of 
the tumor (moderate response); mrTRG4, obvious tumor with 
little fibrosis (slight response); and mrTRG5, same appearance 
and signal intensity of the tumor (no response) [14]. Magnetic 
resonance EMVI (mrEMVI) is defined as the tumor invasion of 
veins beyond the muscularis propria layer and is classified into 
4 scores. Score 0 means no vessel close to extramural penetration 
of the tumor; score 1, normal caliber vessel with no tumor signal 
intensity; score 2, slightly expanded vessel with no signal inten-
sity; score 3, expanded vessel with intermediate signal tumor in-
tensity; and score 4, irregular vessel contour by tumor signal in-
tensity. mrEMVI is considered negative for scores 0, 1, and 2 and 
positive for scores 3 and 4 [15].
Routine follow-up strategy was not conducted in our patients 
because some of them demonstrated early metastasis while others 
showed metastasis late in the waiting period; this would lead to 
changes in the follow-up schedule. Despite this, during the follow-
up visits, serum CEA level, abdominopelvic CT, and chest CT were 
performed for the patients while total colonoscopy, positron emis-
sion tomography CT scan, and pelvic MRI were only performed 
in cases of recurrence.
The data for 14 patients were analyzed using IBM SPSS Statistics 
ver. 25 (IBM Corp., Armonk, NY, USA). The variables had been 
expressed as the number of patients (percentage), median (range), 
or mean± standard deviation.
RESULTS
Patients’ characteristics 
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tients (1.3%) met the inclusion criteria were enrolled. The median 
age of the patients was 63 years (range, 41 to 80 years) with male 
predominance (11 [78.6%] vs. 3 [21.4%]). The median distance of 
the tumor from the anal verge was 7 cm (range, 5 to 10) with 8 pa-
tients (57.1%) of clinical T3 (cT3) stage and 6 (42.9%) of cT4 pa-
tients. The median pre- and post-CRT CEA levels were 4.2 ng/mL 
(0.8 to 95 ng/mL) and 4.7 ng/mL (0.7 to 884 ng/mL), respectively. 
With regard to tumor pathology, more than 57% of the tumors 
were moderately differentiated adenocarcinoma followed by well-
differentiated adenocarcinoma (28.6%), as shown in Table 1.
Initial image (pre-CRT) of the tumors
Table 2 shows the initial radiological characteristics of the tumors. 
mrCRM, lateral pelvic LNs (LPLNs), and mesorectal LNs were 
positive in 12 (85.7%), 6 (42.9%), and 12 patients (85.7%), respec-
tively. mrEMVI was positive in 10 patients (71.4%) (score 3 in 
3 cases and score 4 in 7 cases).
Pre- vs. post-CRT staging 
After CRT, 3 out of 12, 2 out of 10, and 1 out of 6 patients converted 
from positive to negative CRM, EMVI, and LPLNs, respectively, 
as shown in Fig. 1. Conversely, only 4 patients showed downstag-
ing in the T stage. Regarding the tumor response, mrTRG3 (mod-
erate response) was detected in 8 patients while mrTRG4 (slight 
response) and mrTRG5 (no response) were noticed in 5 and 1 pa-
tients, respectively, as demonstrated in Table 3.
Metastases and methods of intervention 
Table 4 shows that the median time for the detection of metastases 
post-CRT was 10 weeks (range, 1 to 59 weeks), and the liver was 
the commonest site of metastasis (10 cases, 71.4%). Furthermore, 
1 patient developed metastases in both the liver and the lung, 
whereas metastases were detected in the liver with the small intes-
tine, the liver with the peritoneum, and the liver with the lung and 
the peritoneum in 3 patients, respectively.
After metastases, 1 patient refused any intervention while 10 
(71.4%) underwent combined surgery (5 received direct surgery 
and the other 5 were administered chemotherapy first followed by 
surgery). Regarding those who underwent combined surgery, 8 
out of 10 received low anterior resection (LAR) (2 open, 5 laparo-
Table 1. Baseline characteristics
Characteristic Value
Age (yr) 63 (41–80)
Sex
   Male 11 (78.6)
   Female 3 (21.4)
Clinical T stage 
   cT3 8 (57.1)
   cT4 6 (42.9)
CEA level (ng/mL)
   Pre-CRT 4.2 (0.8–95)
   Post-CRT 4.7 (0.7–884)
Histopathology of the adenocarcinoma
   Well-differentiated 4 (28.6)
   Moderately differentiated 8 (57.1)
   Poorly differentiated 2 (14.3)
Values are presented as number (%) or median (range).
CEA, carcinoembryonic antigen level; CRT, chemoradiotherapy.
Table 2. Initial image of the tumors
Characteristic Value
Mesorectal LN positive 12 (85.7)
LPLN positive 4 (28.6)
mrCRM positive 12 (85.7)
mrEMVI positive 10 (71.4)
   Score 3 3/10
   Score 4 7/10
Values are presented as number (%) or number only. 
LN, lymph node; LPLN, lateral pelvic LN; mrCRM, magnetic resonance circumfer-
ential resection margin; mrEMVI, magnetic resonance extramural venous invasion.
Fig. 1. Magnetic resonance imaging for 2 patients who showed a re-
sponse after chemoradiotherapy (CRT). (A) Initial (left panel; positive 
mrEMVI) and posttreatment (right panel; negative ymrEMVI) im-
ages of patient 1. (B) Initial (left panel; positive mrCRM and mrEMVI) 
and posttreatment (right panel; negative ymrCRM and ymrEMVI) 
images of patient 12. The arrows show the status of CRM and/or 
EMVI before and after treatment with CRT. mr, magnetic resonance; 
EMVI, extramural venous invasion; y, post-CRT; CRM, circumfer-
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scopic, and 1 robotic) and the other 2 patients underwent open as 
well as laparoscopic ultra-LAR. Meanwhile, 3 patients (21.4%) re-
ceived palliative chemotherapy owing to multiple liver metastases 
in both lobes. Eleven patients (78.6%) presented with progressive 
disease after intervention in the form of local and/or systemic re-
currence; they comprised 3 (21.4%), 2 (14.3%), and 6 (42.9%) 
with recurrence in the liver, peritoneum, and multiple organs, re-
spectively, as shown in Table 4.
DISCUSSION
Nowadays, preoperative CRT followed by TME after an 8- to 10-
week gap is considered the optimal treatment modality for LARC 
with favorable local control; however, distant metastases occurring 
during or after the completion of treatment is the principal mode 
of failure [11].
In our case series, metastases developed in 14 out of 1,092 pa-
tients who received preoperative CRT, constituting 1.3% of the to-
tal patient population. This is a very small number that suggests 
that metastases after CRT may be a rare entity. This result is con-
sistent with those reported by Choi et al. [16], who conducted a 
study for early metastases on 107 patients who received preopera-
tive CRT and only 7 patients (6.5%) developed metastases during 
the waiting period. 
In our study, patients who developed early metastases received 
capecitabine frequently as a radiosensitizer. This does not mean 
that it is a weaker chemotherapeutic agent but inversely its effect 
had been approved by multiple studies [17-19]. This result may be 
attributed to the small number of our patients; hence, further stud-
ies with a larger number of cases are recommended. 
Eleven patients in our study developed systemic metastases after 




cT cN cLPLN mrCRM mrEMVI score yT yN yLPLNs ymrCRM ymrEMVI score mrTRG
  1 T4a 1 Negative Negative 3 T3 1 Negative Negative 2 3
  2 T3 1 Negative Positive 2 T3 1 Negative Threatened 2 4
  3 T4 1 Negative Positive 3 T4 1 Negative Positive 3 3
  4 T3 1 Negative Positive 4 T3 0 Negative Negative 3 3
  5 T4a 1 Negative Positive 4 T4a 1 Negative Positive 3 4
  6 T3 0 Negative Negative 0 T2 0 Negative Positive 0 3
  7 T3 1 Positive Positive 3 T3 1 Positive Negative 3 4
  8 T4a 1 Positive Positive 4 T4a 1 Negative Positive 4 5
  9 T4a 1 Positive Positive 2 T3 1 Positive Positive 2 3
10 T3 0 Positive Positive 4 T3 0 Positive Threatened 4 3
11 T4a 1 Negative Positive 4 T4a 1 Negative Positive 4 4
12 T3 1 Negative Positive 4 T3 1 Negative Negative 2 4
13 T3 1 Positive Positive 2 T2 1 Positive Threatened 2 3
14 T3 1 Positive Positive 4 T3 1 Positive Threatened 3 3
CRT, chemoradiotherapy; c, clinical; T, tumor stage; N, lymph node stage; LPLN, lateral pelvic lymph nodes stage; mr, magnetic resonance; CRM, circumferential resection 
margin; EMVI, extramural venous invasion; y, post-CRT stage; TRG, tumor regression grade. 
Table 4. Metastases and methods of intervention
Characteristic Value
Time to detection of metastases post-CRT (wk) 10 (1–59)
Metastatic organ
   Liver only 10 (71.4)
   Liver and lung 1 (7.1)
   Others 3 (21.4)
Methods of intervention after metastases 
   No 1 (7.1)
   Surgery 5 (35.7)
   Chemotherapy first then surgery 5 (35.7)
   Palliative chemotherapy 3 (21.4)
Systemic recurrence after an intervention 11 (78.6)
Systemic recurrence organ
   No 3 (21.4)
   Multiple liver metastases 3 (21.4)
   Peritoneal carcinomatoses 2 (14.3)
   Multiple organs metastases 6 (42.9)
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the intervention, of whom 6 developed multiple organ metastases 
and 3 presented with multiple liver metastases after they received 
a combined surgery of TME with wedge resection of the liver. Mean-
while, 2 patients developed peritoneal carcinomatosis after they 
underwent ultra-LAR with cytoreductive surgery and hyperther-
mic intraperitoneal chemotherapy. These results denote a poor 
prognosis for patients who developed early metastasis after CRT 
and were managed by any type of intervention. 
In our series, we obtained a non-good or complete response af-
ter CRT according to the mrTRG score and this is considered a 
risk factor for metastasis [20]. This may be due to the high rate of 
positive mesorectal LNs, positive mrCRM, positive mrEMVI, and 
moderately differentiated adenocarcinoma, which are the chief 
risk factors for metastasis [21, 22].
Consequently, despite the median duration of 10 weeks after CRT, 
only 4 patients (28.5%) showed downstaging in the T stage which 
was less than the proportion of patients (41.2%) reported by Yeo 
et al. [23]. Contrarily, 12 (85.7%) of our patients presented with 
involved mrCRM; this is a higher rate than that reported in the 
available literature (4% to 18%) [24] and only 3 of them (25.0%) 
converted to free CRM after CRT. This low rate of response and a 
higher rate of involvement may be considered the cause of metas-
tases [25], poor prognosis, and relapse [26]. 
In a previous study [27] comparing positive and negative mrEMVI, 
the risk of distant metastasis was 4 times increased in positive cases 
(52%) than that in negative ones (12%). In our study, the rate of 
baseline mrEMVI-positive status was high (71.4%) and the response 
to CRT was slight to moderate (2 cases only out of 10 with mrTRG 
3 and 4). Our results support the poor prognosis of patients with 
initial positive mrEMVI and their poor response to CRT. This group 
of patients may be considered resistant to the standard CRT regi-
men; hence, other treatment strategies such as induction or con-
solidation chemotherapy should be considered for those patients.
To date, multiple questions have been asked about patients who 
will not respond to preoperative CRT and who will develop early 
metastases either during or after completion of treatment [16]. 
Therefore, from a practical point of view, changing the chemother-
apy regimen and/or radiation treatment dose with a short and 
meticulous follow-up period may help in detecting non-respond-
ers early and give a chance to modify the treatment protocol. 
Our study has the limitations of being a retrospective study with 
a small number of cases. Nevertheless, to our knowledge, our study 
is the first to summarize the characteristics of patients presented 
with newly developed metastases after completion of CRT and 
before surgery. 
In conclusion, although metastasis after CRT is a rare entity, it 
should not be neglected. In our study, patients who developed me-
tastases after CRT had a middle third LARC with grade II adeno-
carcinoma, and the liver was the commonest site. Patients with 
advanced status which were positive mesorectal LNs, positive 
mrRCM and positive mrEMVI should be closely evaluated in re-
staging period. Despite a long waiting period after CRT, poor re-
sponder can show the metastases during restaging period. Further 
studies with a larger number of patients are needed to treat those 
patients who showed early metastases after CRT.
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